Gene Therapy Briefs

Abstract

Get full access to this article

View all access options for this article.

References

BioMarin Pharmaceutical. 2016. BioMarin provides positive proof-of-concept data for BMN 270 gene therapy in hemophilia A in late breaking oral presentation at the World Federation of Hemophilia (WFH) 2016 World Congress. Available at: http://investors.bmrn.com/releasedetail.cfm?ReleaseID=981465 (accessed August 1, 2016).

Xinhua. 2016. China exclusive: Chinese scientists pioneer human genetic editing. August 2. Available at: http://news.xinhuanet.com/english/2016-08/02/c_135558101.htm (accessed August 7, 2016).

Reardon

. 2016. First CRISPR clinical trial gets green light from US panel. Nature, June 22. Available at: http://www.nature.com/news/first-crispr-clinical-trial-gets-green-light-from-us-panel-1.20137 (accessed August 7, 2016).

Audentes Therapeutics. 2016. Audentes Therapeutics announces pricing of initial public offering. Available at: http://investors.audentestx.com/phoenix.zhtml?c=254280&p=RssLanding&cat=news&id=2186603 (accessed August 1, 2016).

Fidler

. 2016. Audentes prices $75M IPO as gene therapy eyes first U.S. approval. Xconomy, July 20. Available at: http://www.xconomy.com/san-francisco/2016/07/20/audentes-prices-75m-ipo-as-gene-therapy-eyes-first-u-s-approval/ (accessed August 1, 2016).

Audentes Therapeutics. 2016. Prospectus filed pursuant to Rule 424(b)(4). Available at: http://services.corporate-ir.net/SEC.Enhanced/SecCapsule.aspx?c=254280&fid=14493314 (accessed August 2, 2016).

Ziopharm Oncology. 2016. Ziopharm issues statement regarding phase I study of gene therapy candidate Ad-RTS-hIL-12 in brain cancer. Available at: http://ir.ziopharm.com/releasedetail.cfm?ReleaseID=979750 (accessed August 1, 2016).

Ziopharm Oncology. 2016. Ziopharm provides update regarding phase I study of gene therapy candidate Ad-RTS-hIL-12 in brain cancer. Available at: http://ir.ziopharm.com/releasedetail.cfm?ReleaseID=980076 (accessed August 1, 2016).

Spark Therapeutics and Pfizer. 2016. Spark Therapeutics and Pfizer announce receipt of FDA Breakthrough Therapy Designation for SPK-9001 for the treatment of hemophilia B. Available at: http://ir.sparktx.com/phoenix.zhtml?c=253900&p=irol-newsArticle&ID=2187058 (accessed August 5, 2016).

10.

Spark Therapeutics and Pfizer. 2016. Spark Therapeutics and Pfizer announce updated data from first cohort in hemophilia B phase 1/2 trial demonstrating consistent, sustained therapeutic levels of factor IX activity. Available at: http://ir.sparktx.com/phoenix.zhtml?c=253900&p=irol-newsArticle&ID=2187752 (accessed August 5, 2016).

11.

AveXis. 2016. AveXis receives U.S. FDA Breakthrough Therapy Designation for AVXS-101 gene replacement therapy for spinal muscular atrophy type 1. Available at: http://investors.avexis.com/phoenix.zhtml?c=254285&p=irol-newsArticle&ID=2186665 (accessed August 5, 2016).

12.

Pfizer. 2016. Pfizer aims to become industry leader in gene therapy with acquisition of Bamboo Therapeutics, Inc. Available at: http://www.pfizer.com/news/press-release/press-release-detail/pfizer_aims_to_become_industry_leader_in_gene_therapy_with_aquisition_of_bamboo_therapeutics_inc (accessed August 1, 2016).